Caribou Biosciences Long Term Debt

Caribou Biosciences (CRBU) currently reports a long-term debt of $25M as of June 2026. That compares with $47M in the prior-year period — down 46.4% year over year. Use the charts on this page to explore Caribou Biosciences's long-term debt history and peer comparisons.

Caribou Biosciences's long-term debt decreased from $47M to $25M — a 46.4% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Caribou Biosciences reported $25M in long-term debt as of June 2026. That compares with $47M in the prior-year period — down 46.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $25M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Caribou Biosciences, and consider following CRBU for alerts when major investors trade the stock.

Caribou Biosciences is classified in the Healthcare sector. On long-term debt, it currently shows $25M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CRBU with unrelated industries.